Bromocriptine and pyridoxine improve quality of life in women with premenstrual syndrome

Abstract

Objectives: Premenstrual symptoms may affect quality of life (QoL) by negatively affecting behavior and interfering with daily activities in women. In this randomized placebo-controlled clinical trial performed in women with premenstrual syndrome (PMS), treatment with bromocriptine and pyridoxine was evaluated with respect to their impact on QoL. Methods: Women diagnosed with PMS, completed the short form of the Quality of Life Enjoyment and Satisfaction [QOLES] questionnaire before and after treatment. They were treated with placebo, bromocriptine 1.255 mg/day or pyridoxine 100 mg/day for 3 consecutive cycles. Results: A one-way MANOVA revealed a significant multivariate main effect for bromocriptine and pyridoxine treatment (p < 0.001) given for 3 months. Bromocriptine caused a significant improvement in mean scores of six items related to physical health and mood. Women treated with pyridoxine scored significantly better on all the dimensions of QOLES questionnaire. Conclusions: A holistic approach targeting all aspects of QoL, needs to be acquired in the management of PMS. In conclusion, pyridoxine treatment may offer improvement in all aspects of QoL in women with PMS.